Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study
Scandinavian Journal of Urology · 2024
DOI: 10.2340/sju.v59.40001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Urology, 2024. Verfasst von Pietro Scilipoti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Surgical Sciences, Uppsala University, Up…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Urinary Bladder Neoplasms, Prostatectomy, Cystectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Uppsala Universitet.
Abstract (Originalsprache)
Background and aims: One out of three men who undergo cystoprostatectomy for bladder cancer is diagnosed with incidental prostate cancer (PCa) at histopathological examination. Many of these men are PSA tested as part of their follow-up, but it is unclear if this is needed. The aim of this study was to assess the risk of PCa death in these men and the need of PSA-testing during follow-up.
Methods
Between 2002 and 2020, 1,554 men were diagnosed with PCa after cystoprostatectomy performed for non-metastatic bladder cancer and registered in the National Prostate Cancer Register (NPCR) of Sweden. We assessed their risk of death from PCa, bladder cancer and other causes up to 15 years after diagnosis by use of data in The Cause of Death Register. The use of androgen deprivation therapy (ADT) as a proxy for PCa progression was assessed by fillings in The Prescribed Drug Register.
Results
Fifteen years after diagnosis, cumulative incidence of death from PCa was 2.6% (95% CI 2.3%–2.9%), from bladder cancer 32% (95% CI: 30%–34%) and from other causes 40% (95% CI: 36%–44%). Only 35% of men with PCa recorded as primary cause of death in The Cause of Death Register had started ADT before date of death, indicating sticky-diagnosis bias with inflated risk of PCa death.
Conclusions
For a large majority of men diagnosed with incidental PCa at cystoprostatectomy performed for bladder cancer, the risk of PCa death is very small so there is no rationale for PSA testing during follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Experimental Oncology/Unit of Urology, IRCCS Ospedale San Raffaele, Milan, Italy; Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Department of Urology Skåne University Hospital, Malmö, Sweden; Institution of Translational Medicine, Lund University, Malmö, Sweden.
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. marcus.westerberg@uu.se.
ORCID-Profile: Pietro Scilipoti, Fredrik Liedberg, Hans Garmo, Andri Wilberg Orrason, Pär Stattin, Marcus Westerberg
Förderung
- Vetenskapsrådet
- Cancerfonden
- Uppsala Universitet
- Region Uppsala
Zitieren
APA
Scilipoti, P., Liedberg, F., Garmo, H., Orrason, A. W., Stattin, P., & Westerberg, M. (2024). Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scandinavian Journal of Urology. https://doi.org/10.2340/sju.v59.40001
Vancouver
Scilipoti P, Liedberg F, Garmo H, Orrason AW, Stattin P, Westerberg M. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study. Scandinavian Journal of Urology. 2024. doi:10.2340/sju.v59.40001
BibTeX
@article{Scilipoti2024,
author = {Scilipoti, Pietro and Liedberg, Fredrik and Garmo, Hans and Orrason, Andri Wilberg and Stattin, Pär and Westerberg, Marcus},
title = {Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study},
journal = {Scandinavian Journal of Urology},
year = {2024},
doi = {10.2340/sju.v59.40001}
}
EUVIMED